A股異動丨片仔癀(600436.SH)漲近5% 三季度淨利創新高
格隆匯10月19日丨片仔癀(600436.SH)早盤股價拉昇,現漲4.66%,報443.75元,成交超13億元,總市值為2667億元。10月16日,片仔癀發佈三季報,第三季度實現營業收入26.29億元,同比增長24.09%;實現淨利潤8.96億元,同比增長93.08%,創下自上市以來單季度最高淨利潤。國盛證券指出片仔癀三季報業績明顯超出全市場所有預期,主要原因是片仔癀系列藥品增速加快以及整體利潤率明顯提升所致。而公司新增線上片仔癀大藥房天貓旗艦店和片仔癀大藥房京東旗艦店,直銷佔比增加是三季度利潤率大幅提升,業績超預期的核心因素。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.